BLA 761339 · Regeneron Pharmaceuticals
Veopoz
Pozelimab-Bbfg · Injection · Complement Inhibitor
NovelPriority reviewOrphanCDER novel approval, Aug 18, 2023: To treat patients 1 year old and older with CD55-deficient protein-losing enteropathy (PLE), also known as CHAPLE disease
Last checked: Nov 20, 2026Latest source record: Aug 18, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2023
Aug 18, 2023
Approved uses
1
Original approval plus efficacy supplements
Registered trials
15
8 Phase 3, 5 recruiting
FAERS reports
4
4 serious, 1 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: SERIOUS MENINGOCOCCAL INFECTIONS Life-threatening and fatal meningococcal infections have occurred in patients treated with complement inhibitors. Meningococcal infection may become rapidly life-threatening or fatal if not recognized and treated early. Complete or update meningococcal vaccination (for serogroups A, C, W and Y, and serogroup B) at least 2 weeks prior to administering the first dose of VEOPOZ, unless the risks of delaying therapy outweigh the risk of developing a meningococcal infection. Follow the most current Advisory Committee on Immunization Practices (ACIP) recommendations for meningococcal vaccination in patients receiving a complement inhibitor. Patients receiving VEOPOZ are at increased risk for invasive disease caused by N. meningitidis , even if they develop antibodies following vaccination. Monitor patients for early signs of meningococcal infections...
What it is approved for
From the label in effect Dec 4, 2025.
VEOPOZ is indicated for the treatment of adult and pediatric patients 1 year of age and older with CD55-deficient protein-losing enteropathy (PLE), also known as CHAPLE disease. VEOPOZ is a complement inhibitor indicated for the treatment of adult and pediatric patients 1 year of age and older with CD55-deficient protein-losing enteropathy (PLE), also known as CHAPLE disease. ( 1 )
Mechanism: Pozelimab-bbfg is a human, monoclonal immunoglobulin G4 P (IgG4 P ) antibody directed against the terminal complement protein C5 that inhibits terminal complement activation by blocking cleavage of C5 into C5a (anaphylatoxin) and C5b, thereby blocking the formation of the membrane-attack complex (C5b-C9, a structure mediating cell lysis).
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Aug 18, 2023 Original approval · Type 1 - New Molecular Entity · priority review NovelOrphanLabelMedication GuideLetter
1 products under this application
- VEOPOZ · POZELIMAB-BBFG 400MG/2ML(200MG/ML) · INJECTABLE, INJECTION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Pozelimab" as an intervention, any sponsor and status, largest first.
- A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic AtrophyPivotal-lookingRecruiting
Regeneron PharmaceuticalsRegeneron (REGN)
NCT06541704 · 975 participants (planned) · Start Oct 30, 2024 · Primary completion Jul 31, 2028
Drug: Pozelimab; Cemdisiran and 1 more · For: Age-related Macular Degeneration (AMD); Geographic Atrophy (GA)
Sites: Chandler, Arizona; Phoenix, Arizona; Scottsdale, Arizona · 233 sites in all
- A Study to Test How Safe Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Alone Are and How Well They Work in Adult Patients With Generalized Myasthenia GravisPivotal-lookingActive, not recruiting
Regeneron PharmaceuticalsRegeneron (REGN)
NCT05070858 · 288 participants · Start Dec 14, 2021 · Primary completion Jul 8, 2025
Drug: Pozelimab + Cemdisiran; Cemdisiran and 1 more · For: Generalized Myasthenia Gravis
Sites: Scottsdale, Arizona; Irvine, California; Los Angeles, California · 116 sites in all
- A Study in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) to Evaluate How Safe Long-term Treatment With Pozelimab + Cemdisiran Combination Therapy is and How Well it WorksPivotal-lookingRecruiting
Regeneron PharmaceuticalsRegeneron (REGN)
NCT05744921 · 202 participants (planned) · Start Mar 7, 2023 · Primary completion Oct 10, 2028
Drug: Pozelimab; Cemdisiran · For: Paroxysmal Nocturnal Hemoglobinuria
Sites: Curitiba, Brazil; São Paulo, Brazil; Toronto, Canada · 50 sites in all
Regeneron PharmaceuticalsRegeneron (REGN)
NCT05133531 · 202 participants · Start Aug 1, 2022 · Primary completion Sep 28, 2026
Drug: Ravulizumab; Pozelimab and 2 more · For: Paroxysmal Nocturnal Hemoglobinuria
Sites: Whittier, California; Santo André, Brazil; São Paulo, Brazil · 68 sites in all
Regeneron PharmaceuticalsRegeneron (REGN)
NCT07230834 · 54 participants (planned) · Start Jan 19, 2026 · Primary completion Jul 3, 2028
Drug: Pozelimab · For: Geographic Atrophy (GA)
Sites: Lakewood, Colorado; East Weymouth, Massachusetts; Austin, Texas · 9 sites in all
Regeneron PharmaceuticalsRegeneron (REGN)
NCT04491838 · 40 participants · Start Aug 3, 2020 · Primary completion Mar 5, 2021
Drug: Pozelimab · For: Healthy Volunteer
Sites: Antwerp, Belgium
- A Study to Evaluate How Pozelimab + Cemdisiran Combination Therapy Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Whose Current Treatment is Not Working EfficientlyPivotal-lookingRecruiting
Regeneron PharmaceuticalsRegeneron (REGN)
NCT07154745 · 35 participants (planned) · Start Jun 11, 2026 · Primary completion Jan 18, 2030
Drug: Pozelimab; Cemdisiran · For: Paroxysmal Nocturnal Hemoglobinuria
Sites: Ribeirão Preto, Brazil; Santo André, Brazil; São Paulo, Brazil · 20 sites in all
Regeneron PharmaceuticalsRegeneron (REGN)
NCT04940364 · 30 participants · Start Aug 4, 2021 · Primary completion Jun 22, 2022
Drug: Pozelimab; Cemdisiran · For: Healthy
Sites: London, United Kingdom
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug effect less than expected1
- hepatitis1
- injection site reaction1
- meningococcal infection1
- seizure1
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2023 | 1 |
| 2024 | 3 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Evaluating the efficacy and safety of pozelimab in patients with CD55 deficiency with hyperactivation of complement, angiopathic thrombosis, and protein-losing enteropathy disease: an open-label phase 2 and 3 study.
Ozen A, Chongsrisawat V, Sefer AP, et al. · Lancet 2024 · Clinical Trial, Phase I, Clinical Trial, Phase II
- Pozelimab for CHAPLE disease: results from in-trial interviews and clinical outcome assessments.
Litcher-Kelly L, Ozen A, Ollis S, et al. · Orphanet J Rare Dis 2024 · Clinical Trial, Phase II, Clinical Trial, Phase III
- Efficacy and safety of cemdisiran siRNA in myasthenia gravis (NIMBLE): a double-blind, randomised, placebo-controlled, phase 3 trial.
Vu T, Habib AA, Jacob S, et al. · Lancet 2026 · Randomized Controlled Trial, Clinical Trial, Phase III
- The patient experience of CHAPLE disease: results from interviews conducted as part of a clinical trial for an ultra-rare condition.
Litcher-Kelly L, Ozen A, Ollis S, et al. · Orphanet J Rare Dis 2025 · Clinical Trial, Phase II, Clinical Trial, Phase III
Sponsor: Regeneron
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.